SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,591,588 | -7.2% | 166,544 | +1.2% | 0.01% | -16.7% |
| Q2 2023 | $4,947,214 | +78389.8% | 164,578 | -5.4% | 0.01% | -25.0% |
| Q1 2023 | $6,303 | +7.1% | 173,966 | +5.5% | 0.01% | 0.0% |
| Q4 2022 | $5,884 | -99.9% | 164,951 | +2.3% | 0.01% | 0.0% |
| Q3 2022 | $5,460,000 | +22.4% | 161,304 | +4.6% | 0.01% | +14.3% |
| Q2 2022 | $4,461,000 | -6.9% | 154,262 | +4.0% | 0.01% | +16.7% |
| Q1 2022 | $4,794,000 | +13.5% | 148,330 | +2.4% | 0.01% | +20.0% |
| Q4 2021 | $4,224,000 | +7.8% | 144,853 | -1.4% | 0.01% | 0.0% |
| Q3 2021 | $3,919,000 | -23.0% | 146,958 | -11.0% | 0.01% | -28.6% |
| Q2 2021 | $5,087,000 | +16.5% | 165,204 | -0.9% | 0.01% | +16.7% |
| Q1 2021 | $4,365,000 | +7.0% | 166,723 | +2.8% | 0.01% | 0.0% |
| Q4 2020 | $4,081,000 | +27.9% | 162,202 | +5.9% | 0.01% | +20.0% |
| Q3 2020 | $3,191,000 | -22.1% | 153,098 | -11.2% | 0.01% | -28.6% |
| Q2 2020 | $4,096,000 | +35.6% | 172,470 | +2.7% | 0.01% | +16.7% |
| Q1 2020 | $3,021,000 | -22.8% | 167,936 | +1.8% | 0.01% | -14.3% |
| Q4 2019 | $3,915,000 | -7.7% | 165,038 | +6.9% | 0.01% | -12.5% |
| Q3 2019 | $4,241,000 | -15.1% | 154,322 | +2.2% | 0.01% | -11.1% |
| Q2 2019 | $4,998,000 | -1.6% | 151,042 | +4.2% | 0.01% | -10.0% |
| Q1 2019 | $5,080,000 | +5.9% | 144,963 | +0.4% | 0.01% | 0.0% |
| Q4 2018 | $4,795,000 | -20.1% | 144,347 | +21.1% | 0.01% | -16.7% |
| Q3 2018 | $6,001,000 | -17.6% | 119,194 | -2.0% | 0.01% | -20.0% |
| Q2 2018 | $7,282,000 | +35.4% | 121,666 | +3.6% | 0.02% | +36.4% |
| Q1 2018 | $5,378,000 | +19.0% | 117,418 | +3.6% | 0.01% | +22.2% |
| Q4 2017 | $4,518,000 | +16.7% | 113,387 | +17.2% | 0.01% | +12.5% |
| Q3 2017 | $3,870,000 | -4.4% | 96,757 | +3.0% | 0.01% | -11.1% |
| Q2 2017 | $4,047,000 | +38.1% | 93,907 | +0.3% | 0.01% | +28.6% |
| Q1 2017 | $2,930,000 | +78.0% | 93,619 | +43.6% | 0.01% | +75.0% |
| Q4 2016 | $1,646,000 | +9.0% | 65,199 | +6.8% | 0.00% | 0.0% |
| Q3 2016 | $1,510,000 | +44.2% | 61,048 | +18.8% | 0.00% | +33.3% |
| Q2 2016 | $1,047,000 | +72.2% | 51,383 | +28.8% | 0.00% | +50.0% |
| Q1 2016 | $608,000 | +14.3% | 39,898 | +0.7% | 0.00% | 0.0% |
| Q4 2015 | $532,000 | +6.4% | 39,618 | +11.2% | 0.00% | 0.0% |
| Q3 2015 | $500,000 | -11.8% | 35,618 | +6.7% | 0.00% | 0.0% |
| Q2 2015 | $567,000 | +71.3% | 33,382 | +22.1% | 0.00% | +100.0% |
| Q1 2015 | $331,000 | +77.0% | 27,342 | +21.3% | 0.00% | 0.0% |
| Q4 2014 | $187,000 | -1.6% | 22,542 | +3.2% | 0.00% | 0.0% |
| Q3 2014 | $190,000 | -20.5% | 21,842 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $239,000 | +117.3% | 21,842 | +77.5% | 0.00% | – |
| Q1 2014 | $110,000 | +13.4% | 12,302 | -4.4% | 0.00% | – |
| Q4 2013 | $97,000 | +3.2% | 12,862 | 0.0% | 0.00% | – |
| Q3 2013 | $94,000 | +11.9% | 12,862 | -1.0% | 0.00% | – |
| Q2 2013 | $84,000 | – | 12,996 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |